Yes, it did seem like an eternity between Phase 1 and Phase 2, and it was years. The company has made mistakes in the past which did impact the timeframe (indirectly I believe). However, we've had the open label -202 study present interim data 6 weeks ago, final 12 month data is due out in 1H CY25, the -201 study is due to report data in January '25, and the BioMUSE study is ongoing. The purpose of the BioMUSE study is to guide and shape the Phase 2 & 3 studies. With all this data, I am confident that Phase 3 wont take as long to get started as what Phase 2 did.
What to hopefully look forward too, page-38
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.62M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $2.017K | 651.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 44 | 55391134 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 128926244 | 20 |
View Market Depth
| Last trade - 15.24pm 04/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |